Skip to content

META English logo

Main menu
    • About us
      • Vision, mission and values
      • Diversity, equity & inclusion
      • Executive Leadership Team
      • Global Leaders
      • Board of Directors
      • Our leaders
    • Environmental, social & governance
    • Policies & positions
    • Suppliers
    • Media
    • Press releases
    • Women’s Health Accelerator
    • Rahet Bally x Organon
    • Investor relations overview
    • SEC filings
  • Join our team

Contact Us

Main menu

Organon site directory

  • Organon

    • Brazil
    • Canada  English  ·  French
    • Latin America
    • Mexico
    • USA
  • Organon

    • Austria
    • Belgium  Dutch  ·  English  ·  French
    • Bulgaria
    • Czech Republic
    • Denmark
    • Estonia
    • Finland
    • France
    • Germany
    • Hungary
    • Ireland
    • Italy
    • Latvia
    • Lithuania
    • Luxembourg  English  ·  French
    • Netherlands  Dutch  ·  English
    • Norway
    • Poland
    • Portugal
    • Romania
    • Russia
    • Serbia
    • Slovakia
    • Slovenia
    • Spain
    • Sweden
    • Switzerland  French  ·  German  ·  English
    • Ukraine  Ukrainian  · 
    • United Kingdom
  • Organon

    • Australia
    • Hong Kong, China
    • Indonesia
    • Japan
    • Malaysia
    • New Zealand
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Organon

    • Egypt
    • Israel
    • Jordan
    • KSA
    • Kuwait
    • Lebanon
    • Northwest Africa  French  ·  Arabic  ·  Turkey
    • Oman
    • South Africa
    • Turkey
    • UAE
View all locations and contact information

What can we help you find?

Search for:

Global Leaders

Our leadership team manages the strategic direction and operations of our company. With their broad and varied experiences, they guide who we are and what we stand for.

Photo of Rebecca Lowell Edwards

Rebecca Lowell Edwards, Chief Communications Officer

Photo of Michael Pergine

Michael Pergine, Chief Government Affairs & Policy Officer

Photo of Daniel Karp

Daniel Karp, Chief Business Development Officer

Photo of Susan O’Neal

Susan O’Neal, Chief Ethics & Compliance Officer

Photo of Julie Pentz

Julie Pentz, Chief Procurement Officer

Photo of Juliana Papa Drinane

Juliana Papa Drinane, Head of Supply Chain Management

Photo of Jennifer Halchak

Jennifer Halchak, Head of Investor Relations

Photo of Iris Melendez

Iris Melendez, Head of Talent and Diversity

Photo of Charlotte Owens

Charlotte Owens, Head of Medical Affairs & Outcomes Research

Photo of Mazen Altaruti

Mazen Altaruti, Regional Lead, Emerging Markets

Photo of Meghan Rivera

Meghan Rivera, Managing Director, U.S. Market Lead

Photo of Zafer Unluer

Zafer Unluer, Managing Director, China Market Lead

Photo of Nico Van Hoecke

Nico Van Hoecke, Europe & Canada Regional Lead

Photo of Joe Azzinaro

Joe Azzinaro, Global Biosimilars Commercial Lead

Photo of Ger Brennan

Ger Brennan, Global Established Brands Commercial Lead

Photo of Simon Holland

Simon Holland, Global Women’s Health Commercial Lead

Photo of Colby Holtshouse

Colby Holtshouse, Global MedTech Commercial Lead

Photo of Jeremy Sowers

Jeremy Sowers, Global Fertility Commercial Lead

META English logo

Company

  • About us
  • Our leaders
  • Environmental, social & governance

Resources

  • Patient resources
  • Investor relations
  • Media

Contact us

  • Contact Us
  • Contact information
  • Global locations
  • Forward-Looking Statement
  • cookie policy
  • Privacy
  • Terms of Use
  • Sitemap
© 2025 Organon group of companies. All rights reserved. ORGANON and the ORGANON Logo are trademarks of the Organon group of companies.

You are leaving Organon.com

Cancel Continue Opens a new window

Forward-looking statement of Organon

This news release of Organon (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the recent global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2020 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov Opens a new window ).

No Duty to Update

The information contained in this website was current as of the date presented. The company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the website and investors should not rely upon the information as current or accurate after the presentation date.

Decline Accept